youtube_live
Q3 2026 earnings • released • Revenue miss -62.61%
See resultschevron_right
ALCLS:EPA
Cellectis SA
€1.06
arrow_downward
-17.50%(-0.22) 1D
Nov 13, 5:35:11 PM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALCLS...
Open
€1.07
High
€1.17
Low
€1.01
Mkt. cap
90.32M
Avg. vol.
404.58K
Volume
1.98M
52-wk high
€4.75
52-wk low
€0.90
EPS
-€0.59
Shares outstanding
72.09M
No. of employees
227
Open
€1.07
High
€1.17
Low
€1.01
Mkt. cap
90.32M
Avg. vol.
404.58K
Volume
1.98M
52-wk high
€4.75
52-wk low
€0.90
EPS
-€0.59
Shares outstanding
72.09M
No. of employees
227
News stories
From web sources and news partners
GuruFocus
·
1 day ago
Cellectis SA (CLLS) (Q3 2026) Earnings Call Highlights: Strategic Shift to Gene Editing Reshapes Growth Outlook
TradingView
·
1 day ago
What Cellectis (CLLS) Said on Its Q3 Earnings Call
Investing.com UK
·
1 day ago
Earnings call transcript: Cellectis Q3 2026 loss widens as revenue misses forecast
TradingView
·
1 day ago
Cellectis Q3 2026 Earnings Call Is Live
Profile
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
About Cellectis SA
CEOAndré Choulika
Employees227
Founded1999
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitecellectis.com